Redirecting NaV1.7 Trafficking to Deliver Selective Pain Relief Without CNS Liabilities

• Targeting the CRMP2–SUMOylation pathway to indirectly regulate NaV1.7 surface expression and DRG excitability  
• Demonstrating a differentiated strategy to overcome the clinical limitations of direct NaV1.7 pore blockers  
• Advancing small molecules against the CRMP2–SUMO interface toward first-in-human development through NIH collaboration 

Speakers:

Rajesh Khanna

Chief Scientific Officer

Regulonix